Jennison Associates’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Jennison Associates’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-122,495	Closed	-$13.1M	–	639
2023 Q1	$13.1M	Buy	122,495 +57	+0%	+$6.56K	0.01%	359
2022 Q4	$13.5M	Buy	+122,438	New	+$7.94M	0.01%	369

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Jennison Associates's RXDX Position: Q2 2023 in Review

Jennison Associates sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 122,495 shares — an estimated $13.1M sold.

Jennison Associates first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $13.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Jennison Associates reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jennison Associates sold 122,495 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.1M.
Jennison Associates first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Jennison Associates's Prometheus Biosciences, Inc. Common Stock position peaked at $13.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Jennison Associates's 13F filing for Q2 2023, filed 3 Aug 2023.